亚太药业(002370) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥112,712,517.95, a decrease of 8.80% compared to ¥123,584,310.47 in the same period last year[4] - The net loss attributable to shareholders was ¥2,998,386.71, representing a 14.49% increase in loss from ¥2,618,854.09 year-on-year[4] - Total operating revenue for Q1 2024 was CNY 112,712,517.95, a decrease of 8.5% compared to CNY 123,584,310.47 in the same period last year[19] - Net profit for Q1 2024 was a loss of CNY 2,998,386.71, compared to a loss of CNY 2,618,854.09 in Q1 2023, reflecting a deterioration in performance[20] Cash Flow - The net cash flow from operating activities improved significantly to ¥7,687,843.33, a 408.27% increase from -¥2,493,862.07 in the previous year[4] - Operating cash flow for Q1 2024 was CNY 7,687,843.33, a significant improvement from a negative cash flow of CNY 2,493,862.07 in the same quarter last year[22] - The net cash flow from investing activities was -¥2,890,338.00, a 154.22% increase in cash outflow compared to -¥1,136,941.50 in the previous year[10] - The net cash flow from financing activities was -¥61,901,761.80, a significant increase in cash outflow of 313.20% from -¥14,981,172.78 year-on-year[10] - Cash inflow from financing activities totaled 50,000,000.00, while cash outflow was 61,901,761.80, resulting in a net cash flow of -61,901,761.80, compared to -14,981,172.78 previously[23] - The net increase in cash and cash equivalents was -57,104,256.47, down from -18,611,976.35 in the prior period, reflecting a decline in liquidity[23] - The ending balance of cash and cash equivalents was 663,138,268.39, compared to 703,824,887.55 at the end of the previous period[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,362,635,349.17, down 4.67% from ¥1,429,373,407.82 at the end of the previous year[4] - Total current assets decreased from 955,179,993.71 to 897,221,234.63, a decline of approximately 6.1%[16] - Total liabilities decreased to CNY 784,725,256.60 from CNY 848,498,998.29, indicating improved financial health[20] - Total current liabilities decreased from 161,802,829.27 to 101,490,071.11, a decline of approximately 37.3%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 64,587[12] - The largest shareholder, Ningbo Fubang Holdings, holds 14.68% of shares, totaling 89,420,000 shares[12] Expenses - Total operating costs for Q1 2024 were CNY 114,454,069.55, down 9.4% from CNY 126,382,479.22 year-over-year[19] - Sales expenses decreased to CNY 14,316,311.00 in Q1 2024 from CNY 19,599,947.10 in Q1 2023, a reduction of 26.9%[19] - Financial expenses decreased by 49.00% to ¥5,203,577.16, primarily due to reduced interest expenses on convertible bonds[8] - Financial expenses decreased significantly to CNY 5,203,577.16 from CNY 10,203,797.54, a reduction of 48.9% year-over-year[19] Research and Development - The company has ongoing research and development efforts, with development expenditures increasing from 11,133,234.46 to 12,557,762.76[16] - Research and development expenses for Q1 2024 were CNY 4,643,430.60, slightly up from CNY 4,608,303.89 in Q1 2023, indicating continued investment in innovation[19] Other Information - The company received government subsidies amounting to ¥346,429.75 during the reporting period[6] - The company has not reported any significant changes in shareholder relationships or actions related to share lending[13] - The company did not conduct an audit for the first quarter report, indicating that the figures are unaudited[24] - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[24]